[Indications for infliximab. How long should treatment last? Risk/benefit evaluation]. [electronic resource]
Producer: 20040618Description: 172-6 p. digitalISSN:- 0210-5705
- Antibodies, Monoclonal -- administration & dosage
- Autoimmune Diseases -- etiology
- Colitis, Ulcerative -- therapy
- Contraindications
- Crohn Disease -- therapy
- Drug Administration Schedule
- Drug Hypersensitivity -- etiology
- Heart Failure -- etiology
- Humans
- Hypersensitivity, Delayed -- chemically induced
- Immunologic Surveillance -- drug effects
- Infections -- etiology
- Infliximab
- Infusions, Intravenous
- Lymphoma -- etiology
- Risk Assessment
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.